SARS-CoV-2 ORF1ab A1061S potentiate autoreactive T cell responses via epitope mimicry: an explanation to hepatitis of unknown cause
Abstract
The World Health Organization have recently announced outbreak news of acute, severe hepatitis of unknown cause in children under a Covid-19 pandemic. Whether it is associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is still under debating. Here, we performed genomic sequence alignment analysis of the genome of SARS-Cov-2 (Wuhan-hu-1) to the human genome reference. Sequence analysis revealed that the SARS-CoV-2 ORF1ab 1056-1173 presented high identities with the human protein PAPR14 53-176 (3Q6Z_A). After searching the fully sequenced SARS-CoV-2 genomes deposited in GISAID ( <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.gisaid.org/">https://www.gisaid.org/</ext-link> ), we detected 170 SARS-CoV-2 variants with mutation in ORF1ab 1061 , where alanine (A) was substituted by serine (S). This alteration made a 7-amino acid peptide (VVVNASN) in ORF1ab 1056-1062 identical to its counterpart in PARP14 53-59 (3Q6Z_A). HLA prediction suggested that the peptides with high identities in PARP14 and ORF1ab could be presented by a same globally prevalent HLA-A*11:01 molecule. And in consistent with the first reported case of hepatitis of unknown, SARS-CoV-2 ORF1ab VVVNASN variants were mostly identified as Delta lineages in UK by the late 2021, with an overall frequency of 0.00161%. Thus, our preliminary results raised a possibility that infection by SARS-CoV-2 ORF1ab VVVNASN variant might elicit an autoimmune T cell response via epitope mimicry and is associated with the outbreak of unknown hepatitis. We anticipated that these findings will alert the human societies to pay more attention to rare mutations beyond the spike proteins.
Related articles
Related articles are currently not available for this article.